Syndivia
Develops antibody-drug conjugate candidates and hinge-specific conjugation technology for cancer treatment
Highlights
- New on EvolcAdded 2026-11-14
About Syndivia
Syndivia is a biotechnology company developing antibody-drug conjugates (ADCs) and the GeminiMab platform for site-specific conjugation at the antibody hinge. Its pipeline includes proprietary and partnered programs for cancer indications.
The company is based in Strasbourg, France, and was founded in 2014. Its work focuses on ADCs, conjugation technologies, and related intellectual property.
Product: GeminiMab hinge-conjugation platform and proprietary and partnered antibody-drug conjugate candidates.
Jobs at Syndivia
More biotech & pharma companies
Synthenova
Custom organic chemistry synthesis and R&D contracts for biotech, pharma, cosmetic and chemical companiesNew on EvolcSyntivia
Cosmetic R&D and in vitro testing services for beauty and personal-care companiesNew on EvolcTamrisa
Develops antibiotics and supplies established anti-infective medicines for patients and healthcare marketsYoung companyNew on EvolcTarian Pharma
Developing a topical treatment to prevent skin toxicities in patients receiving cancer therapiesNew on EvolcTebu Bio
Life science research products and CRO services for biotechnology and life sciences researchersTech In Care
Biotechnology research connecting epigenetics, metabolomics and AI to explore biology, environment and healthNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content delivery
- CloudflareHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Content management
- SquarespaceHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.